{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:04:36Z","timestamp":1760187876857},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2000,11]]},"DOI":"10.1006\/gyno.2000.5958","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T22:50:18Z","timestamp":1032303018000},"page":"211-215","source":"Crossref","is-referenced-by-count":34,"title":["Treatment of Relapsed Carcinoma of the Ovary with Single-Agent Paclitaxel Following Exposure to Paclitaxel and Platinum Employed as Initial Therapy"],"prefix":"10.1006","volume":"79","author":[{"given":"Kristine M.","family":"Zanotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome L.","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander W.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth D.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurie","family":"Markman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2000.5958_RF1","series-title":"Principles and Practice of Gynecologic Oncology","first-page":"919","article-title":"Epithelial ovarian cancer","author":"Ozols","year":"1997"},{"key":"10.1006\/gyno.2000.5958_RF2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0090-8258(85)90249-5","article-title":"Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent","volume":"21","author":"Seltzer","year":"1985","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5958_RF3","first-page":"798","article-title":"Re-treatment of patients with recurrent epithelial ovarian cancer with platinum-based chemotherapy","volume":"73","author":"Gershenson","year":"1989","journal-title":"Obstet Gynecol"},{"key":"10.1006\/gyno.2000.5958_RF4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0090-8258(90)90174-J","article-title":"Treatment of relapsed carcinoma of the ovary with cisplating or carboplatin following initial treatment with these compounds","volume":"36","author":"Gore","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5958_RF5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cislatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF6","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1200\/JCO.1998.16.4.1494","article-title":"Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma","volume":"16","author":"Rose","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF7","first-page":"286","article-title":"Second-line paclitaxel therapy in patients with ovarian cancer previously treated with a taxane","volume":"15","author":"Aghajanian","year":"1996","journal-title":"Proc ASCO"},{"key":"10.1006\/gyno.2000.5958_RF8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1006\/gyno.2000.5958_RF11","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF12","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1479-828X.1996.tb03278.x","article-title":"Paclitaxel (Taxol) as salvage therapy for relapsed ovarian cancer","volume":"36","author":"Planner","year":"1996","journal-title":"Aust N Z J Obstet Gynecol"},{"key":"10.1006\/gyno.2000.5958_RF14","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1993.11.12.2405","article-title":"Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103","volume":"11","author":"Trimble","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1200\/JCO.1996.14.3.796","article-title":"Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center Protocol 9103: paclitaxel in refractory ovarian cancer","volume":"14","author":"Markman","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/gyno.1996.4514","article-title":"Taxol as a second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy","volume":"64","author":"Mayerhofer","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5958_RF17","first-page":"223","article-title":"CA125 for the monitoring of ovarian carcinoma during primary therapy","volume":"69","author":"Lavin","year":"1987","journal-title":"Obstet Gynecol"},{"key":"10.1006\/gyno.2000.5958_RF18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0090-8258(88)90244-2","article-title":"Ovarian cancer: The prognostic value of the serum half-life of CA125 during induction chemotherapy","volume":"30","author":"Van der Burg","year":"1988","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.5958_RF19","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European\u2013Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/(SICI)1097-0142(19960701)78:1<118::AID-CNCR17>3.0.CO;2-2","article-title":"CA125: a valid marker in ovarian carcinoma patients treated with paclitaxel?","volume":"78","author":"Davelaar","year":"1996","journal-title":"Cancer"},{"key":"10.1006\/gyno.2000.5958_RF21","doi-asserted-by":"crossref","unstructured":"Pearl, M, L, Yashar, C, M, Johnston, C, M, et al.:Exponential regression of CA125 during salvage treatment of ovarian cancer with taxol. Gynecol Oncol53:339\u2013343, 1994, doi: 10.1006\/gyno.1994.1144","DOI":"10.1006\/gyno.1994.1144"},{"key":"10.1006\/gyno.2000.5958_RF22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.1999.17.2.501","article-title":"Comparison of standard and CA125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel","volume":"17","author":"Bridgewater","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF23","first-page":"1","article-title":"Clinical toxicities encountered with paclitaxel (Taxol)","volume":"20","author":"Rowinsky","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2000.5958_RF24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00001813-199304000-00003","article-title":"The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense Taxol and granulocyte colony stimulating factor","volume":"4","author":"Bicher","year":"1993","journal-title":"Anti-Cancer Drugs"},{"key":"10.1006\/gyno.2000.5958_RF25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000227498","article-title":"Absence of cumulative bone marrow suppression in heavily pretreated ovarian cancer patients undergoing salvage chemotherapy with paclitaxel","volume":"52","author":"Pearl","year":"1995","journal-title":"Oncology"},{"key":"10.1006\/gyno.2000.5958_RF26","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (Taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2000.5958_RF27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin inpatients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2000.5958_RF28","doi-asserted-by":"crossref","unstructured":"Ten Bokkel Huinink, W, Gore, M, Carmichael, J, et al:, Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer, J Clin Oncol, 15: 2183, \u2013 2193","DOI":"10.1200\/JCO.1997.15.6.2183"},{"key":"10.1006\/gyno.2000.5958_RF29","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1200\/JCO.2000.18.8.1733","article-title":"Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials","volume":"18","author":"Rustin","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825800959584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825800959584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T11:22:07Z","timestamp":1576495327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825800959584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["S0090825800959584"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2000.5958","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}